ArticleThe New England journal of medicine2008
Cancer immunotherapy--the endgame begins.
Article in The New England journal of medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers.Expert opinion on emerging drugs · 2025Review
- Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities.Advances in respiratory medicine · 2024Review
- Nano-Delivery of Immunogenic Cell Death Inducers and Immune Checkpoint Blockade Agents: Single-Nanostructure Strategies for Enhancing Immunotherapy.Pharmaceutics · 2024Review
- Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer.Frontiers in immunology · 2024Review
- Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.Frontiers in immunology · 2023Article
- Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates.Cancer communications (London, England) · 2021Review
- Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.Oncotarget · 2017Article
- Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Journal of clinical pharmacology · 2015Review
- Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Critical reviews in immunology · 2014Review
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.The Journal of clinical investigation · 2013Article
- Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.Immunology · 2013Article
- Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction.Frontiers in oncology · 2013Article
- Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future.Oncoimmunology · 2012Article
- Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models.PloS one · 2010Article
- Trends in cancer immunotherapy.Clinical Medicine Insights. Oncology · 2010Article
- Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation.Cancer gene therapy · 2010Article
- DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.Neuro-oncology · 2009Article
- Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.International immunology · 2009Article
Corrections and comments
- Commented on by
- Comment on
- Comment on
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.